Galectin's balance sheet appears structurally impaired, with $137.7M of total debt against just $14.8M in total assets (over 9.3x), negative $136.9M in shareholders' equity, a $446.8M accumulated deficit, and a current ratio that collapsed to 0.10 in 2026Q2 against $13.3M of cash.
Galectin Therapeutics Inc. (GALT) balance sheet — 26-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 |
|---|
| Total Current Assets | 12.9M | 19.44M | 17.25M | 27.71M | 20.55M | 41.82M | 29.46M | 48.21M | 8.83M | 3.82M | 15.79M | 26.4M | 29.66M | 10.69M | 9.52M | 6.5M | 6.2M | 304K | 380K | 1.39M | 5.94M | 4.69M | 10.82M | 7.7M | 1.99M | 1.57M | 210K |
| Cash & Short-Term Investments | 11.71M | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M | 27.14M | 47.48M | 8.25M | 3.05M | 15.36M | 25.85M | 29.13M | 10.49M | 9.36M | 6.4M | 5.89M | 251K | 318K | 1.32M | 5.77M | 4.47M | 10.7M | 7.61M | 1.92M | 1.49M | 210K |
| Cash Only | 11.71M | 17.72M | 15.12M | 25.66M | 18.59M | 39.65M | 27.14M | 47.48M | 8.25M | 3.05M | 15.36M | 25.85M | 29.13M | 10.49M | 9.36M | 6.4M | 5.89M | 251K | 318K | 1.32M | 773K | 4.47M | 10.7M | 7.61M | 1.92M | 1.49M | 210K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 234K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.2M | 1.72M | 2.13M | 2.05M | 1.96M | 2.17M | 2.32M | 729K | 579K | 6K | 6K | 6K | 6K | 0 | 0 | 104K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 80.77K | 0 |
| Total Non-Current Assets | 104K | 96K | 243K | 490K | 733K | 7K | 135K | 258K | 174K | 342K | 1K | 8K | 16K | 26K | 44K | 111K | 105K | 132K | 324K | 393K | 427K | 269K | 286K | 305.73K | 289.2K | 194.61K | 20K |
| Property, Plant & Equipment | 0 | 0 | 0 | 53K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 3K | 8K | 6K | 7K | 17K | 40K | 73K | 112K | 60K | 103K | 144K | 177.16K | 111.54K | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1K | 8K | 15K | 23K | 30K | 36K | 39K | 56K | 225K | 250K | 256K | 209K | 156K | 135K | 85.09K | 56.12K | 10K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 104K | 96K | 243K | 437K | 733K | 7K | 135K | 258K | 174K | 342K | 0 | 0 | 0 | 0 | 6K | 69K | 59K | 59K | 59K | 70K | 59K | 0 | 27K | 26.73K | 26.95K | 26.95K | 10K |
| Total Assets | 13.01M | 19.53M | 17.5M | 28.2M | 21.29M | 41.83M | 29.6M | 48.47M | 9.01M | 4.16M | 15.79M | 26.41M | 29.68M | 10.71M | 9.56M | 6.61M | 6.3M | 436K | 704K | 1.78M | 6.36M | 4.96M | 11.11M | 8M | 2.28M | 1.77M | 230K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 73.19% | 11.64% | -37.96% | 32.49% | -49.11% | 41.31% | -38.93% | 438.16% | 116.44% | -73.66% | -40.19% | -11.02% | 177.02% | 12.05% | 44.6% | 4.95% | 1344.95% | -38.07% | -60.49% | -71.99% | 28.21% | -55.33% | 38.84% | 250.48% | 29.24% | 668.06% | - |
| Total Current Liabilities | 46.41M | 8.03M | 35.41M | 15.68M | 13.01M | 9.03M | 5.4M | 2.82M | 2.11M | 2.97M | 3.78M | 1.36M | 1.7M | 2.49M | 1.64M | 2.21M | 1.77M | 1.05M | 1.08M | 2.6M | 5.99M | 1.38M | 1M | 378K | 666.79K | 550.7K | 180K |
| Accounts Payable | 3.5M | 3.25M | 5.66M | 6.43M | 3.89M | 1.8M | 1.29M | 1.66M | 297K | 608K | 910K | 448K | 906K | 762K | 397K | 384K | 125K | 221K | 447K | 601K | 340K | 295K | 206K | 166K | 302.9K | 236.22K | 80K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 221.92K | 47.45K | 23.36K | - | - | - | - | - | - | 3.33K | 3.43K | 1.85K | - | - | - | - | - | - |
| Short-Term Debt | 33.21M | 0 | 21.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 0 | 0 | 0 | 0 | 0 | 15K | 195K | 80K |
| Deferred Revenue (Current) | 3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 200K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.2M | 1.06M | 1.89M | 8.07M | 8.11M | 6.49M | 3.27M | 147K | 517K | 1.57M | 2.19M | 286K | 193K | 1.2M | 1.2M | 1.25M | 948K | 0 | 0 | 1.9M | 5.14M | 0 | 0 | 0 | 174.25K | 0 | 20K |
| Current Ratio | 0.28x | 2.42x | 0.49x | 1.77x | 1.58x | 4.63x | 5.46x | 17.10x | 4.19x | 1.29x | 4.18x | 19.41x | 17.42x | 4.30x | 5.81x | 2.93x | 3.50x | 0.29x | 0.35x | 0.53x | 0.99x | 3.40x | 10.77x | 20.36x | 2.99x | 2.85x | 1.17x |
| Quick Ratio | 0.28x | 2.42x | 0.49x | 1.77x | 1.58x | 4.63x | 5.46x | 17.10x | 4.19x | 1.29x | 4.18x | 19.41x | 17.42x | 4.30x | 5.81x | 2.93x | 3.50x | 0.29x | 0.35x | 0.53x | 0.99x | 3.40x | 10.77x | 20.36x | 2.99x | 2.85x | 1.17x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 42K | 137.7M | 85.16M | 72.77M | 40.47M | 30.18M | 8K | 52K | 0 | 0 | 0 | 0 | 0 | 0 | 6K | 0 | 6.22M | 3.85M | 94K | 2.11M | 396K | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 0 | 133.74M | 85.11M | 71.74M | 39.83M | 29.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 42K | 3.96M | 47K | 1M | 639K | 1.13M | 8K | 52K | 0 | 0 | 0 | 0 | 0 | 0 | 6K | 0 | 6.22M | 3.85M | 94K | 2.11M | 396K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 46.45M | 145.73M | 120.56M | 88.44M | 53.48M | 39.21M | 5.41M | 2.87M | 2.11M | 2.97M | 3.78M | 1.36M | 1.7M | 2.49M | 1.64M | 2.21M | 7.99M | 4.9M | 1.17M | 4.71M | 6.38M | 1.38M | 1M | 377.91K | 666.79K | 550.7K | 180K |
| Total Debt | 33.21M | 133.76M | 106.25M | 71.81M | 39.87M | 29.06M | 44K | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 0 | 5.14M | 0 | 0 | 0 | 15K | 195K | 80K |
| Net Debt | 21.5M | 116.04M | 91.13M | 46.15M | 21.28M | -10.59M | -27.1M | -47.44M | -8.25M | -3.05M | -15.36M | -25.85M | -29.13M | -10.49M | -9.36M | -6.4M | -5.89M | -251K | -118K | -1.32M | -773K | -4.47M | -10.7M | -7.61M | -1.91M | -1.3M | -130K |
| Debt / Equity | -0.99x | - | - | - | - | 11.11x | 0.00x | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01x | 0.16x | 1.60x |
| Debt / EBITDA | -2.92x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.89x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -1.45x | -3.21x | -7.49x | -13.71x | -36.54x | -61.43x | -268.71x | -151.80x | -40.37x | -1352.92x | - | - | - | - | - | - | - | - | - | -25.95x | -0.73x | - | - | -1254.96x | -7.85x | - | - |
| Total Equity | -33.44M | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M | 24.19M | 45.59M | 6.9M | 1.19M | 12.02M | 25.05M | 27.97M | 8.23M | 7.92M | 4.4M | -1.69M | -4.47M | -469K | -2.92M | -22K | 3.58M | 10.11M | 7.62M | 1.62M | 1.22M | 50K |
| Equity Growth % | 18.06% | -22.44% | -71.1% | -87.12% | -1330.66% | -89.19% | -46.94% | 560.99% | 478.21% | -90.07% | -52.03% | -10.46% | 240.03% | 3.92% | 80.05% | 359.56% | 62.08% | -852.45% | 83.96% | -13190.91% | -100.61% | -64.54% | 32.54% | 371.68% | 32.94% | 2331.69% | - |
| Book Value per Share | -0.37 | -1.97 | -1.65 | -1.00 | -0.54 | 0.04 | 0.42 | 0.87 | 0.18 | 0.03 | 0.41 | 1.04 | 1.28 | 0.49 | 0.52 | 0.37 | -0.18 | -0.56 | -0.06 | -0.45 | -0.00 | 0.79 | 2.35 | 2.14 | 0.59 | 0.54 | 0.02 |
| Total Shareholders' Equity | -33.44M | -126.19M | -103.07M | -60.24M | -32.19M | 2.62M | 24.19M | 45.59M | 6.9M | 1.19M | 12.02M | 25.05M | 27.97M | 8.23M | 7.92M | 4.4M | -1.69M | -4.47M | -469K | -2.92M | -22K | 3.58M | 10.11M | 7.62M | 1.62M | 1.22M | 50K |
| Common Stock | 100K | 65K | 62K | 61K | 59K | 59K | 56K | 56K | 41K | 36K | 33K | 28K | 22K | 18K | 16K | 13K | 64K | 52K | 48K | 40K | 32K | 27K | 27K | 0 | 19.03K | 15.52K | 10K |
| Retained Earnings | -450.36M | -432.55M | -401.57M | -354.37M | -309.57M | -270.69M | -240M | -216.39M | -196.22M | -181.17M | -163.7M | -140.05M | -118.92M | -101.97M | -80.02M | -69.14M | -56.42M | -47.72M | -38.55M | -35.16M | -25.73M | -26.43M | -19.89M | -12.71M | -7.83M | -4.16M | -190K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -309K | -299K | -276K | 0 | 0 | -257K | -1K | -70K | -204.96K | -91.58K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying GALT stock.
As of 2025, Galectin Therapeutics Inc. (GALT) had total assets of $19.5M including $19.4M in current assets.
Galectin Therapeutics Inc. (GALT) carries total debt of $133.8M, offset by $17.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Galectin Therapeutics Inc. (GALT) has total shareholders' equity (book value) of $-126.2M ($-1.97 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Galectin Therapeutics Inc. (GALT) reported a current ratio of 2.42x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Debt Exceeds Assets Tenfold
Metrics are mathematically derived from official filings.
Asset Base Eroding Under Debt Load
According to Galectin's reported balance sheets, total assets contracted 43% from $25.9M in 2024Q1 to $14.8M in 2026Q2 while total liabilities rose 56% to $151.7M, producing a $136.9M equity deficit that signals structurally impaired balance sheet quality.
The trajectory is unambiguously deteriorating: equity has worsened from -$71.1M to -$136.9M over ten quarters, a 93% deepening driven by both the $55.2M increase in total debt and the $11.1M decline in assets. This is not a temporary working-capital swing but a structural imbalance where accumulated deficits compound faster than any asset base the company retains, consistent with the zero-revenue profile identified in the income statement analysis. Investors should note that without a revenue or financing inflection, this trajectory suggests further balance sheet impairment ahead.
Debt Surpasses Total Assets by Ninefold
Based on Galectin's reported figures, total debt reached $137.7M in 2026Q2 against just $14.8M in total assets, representing a debt-to-asset ratio exceeding 9.3x and implying that creditors' claims dwarf the entire asset base by nearly $123M.
The debt build from $82.5M to $137.7M over ten quarters has occurred without any corresponding asset growth, suggesting the financing is funding operating losses rather than productive investment—a pattern typical of convertible-note-dependent biotechs. With no disclosed interest coverage capability from revenue and cash burn still active, the refinancing risk warrants close attention, as the debt appears to be the dominant liability class consuming the balance sheet. The absence of a debt maturity schedule in this dataset means investors should examine the filing for near-term conversion or repayment triggers that could accelerate dilution or default risk.
Current Ratio Collapsed to Danger Zone
As reported in Galectin's quarterly balance sheets, the current ratio plunged from 2.15 in 2026Q1 to 0.10 in 2026Q2, and cash fell to $13.3M against $151.7M in total liabilities, indicating that near-term obligations exceed liquid resources by an order of magnitude.
The sudden current ratio collapse from 2.15 to 0.10 between consecutive quarters is the most alarming liquidity signal in the dataset, suggesting a large current-portion liability was reclassified or a significant debt tranche matured into current status. With cash of $13.3M covering less than 9% of total liabilities and quarterly operating cash outflows still running in the low millions per the cash flow analysis, the buffer against a financing delay appears thin. This combination of a shrinking cash balance and a deteriorating current ratio suggests Galectin is approaching a liquidity inflection point where new financing or restructuring becomes urgent rather than discretionary.
Accumulated Deficit Swallows Negative Equity
According to Galectin's balance sheet disclosures, accumulated losses reached $446.8M as of 2026Q2 against negative shareholders' equity of $136.9M, implying that historical write-downs and financing costs have consumed the entire book value plus an additional $136.9M in creditor-funded obligations.
The $80.9M increase in accumulated deficit over ten quarters far outpaces the $65.8M deterioration in equity, indicating that new debt issuance—likely at a discount or with attached warrants—has partially funded operations while simultaneously eroding per-share book value. The absence of goodwill or meaningful PPE on the balance sheet means there are no tangible assets to liquidate in a downside scenario, leaving convertible debt holders and equity holders competing over a shrinking cash pool. This equity profile implies that common shareholders hold an extremely deep out-of-the-money claim, consistent with the pure-pipeline optionality thesis from the income statement analysis.
Negative Working Capital Masks Convertible Structure
Based on Galectin's reported balance sheets, the $137.7M debt load against $151.7M in liabilities and only $14.8M in assets may understate true economic leverage if the convertible notes carry embedded derivative liabilities or anti-dilution provisions not separately itemized in this summary data.
The most non-obvious risk is that headline leverage metrics may be misleading if a substantial portion of the reported debt is convertible notes with equity-linked features that could trigger massive dilution upon conversion—dilution that would not appear as a liability on the balance sheet but would devastate remaining equity holders. Additionally, the current ratio swing from 2.15 to 0.10 in a single quarter warrants investigation: it may indicate covenant breaches, accelerated repayment demands, or note conversions that could further constrain liquidity. Investors should examine the full 10-Q footnote disclosures for contingent conversion triggers, warrant overhang, and any going-concern language, as these off-summary-sheet features often determine survival outcomes for pre-revenue biotechs in this leverage position.